

Code	GD1009-RV (GeneDetect® rAVE™ Gene Delivery Reagent)
Vector	AAV1/2-CAG-Scrambled Control 3XmiR/GFP-WPRE-BGH-polyA
Vector Description	AAV1/2 Vector. miR scrambled control x3 co-expressing eGFP. The CAG promoter consists of the chicken β -actin promoter hybridized with the CMV immediate early enhancer sequence and is highly efficient in most tissue types. The Woodchuck post-transcriptional regulatory element (WPRE) and the presence of a bovine growth hormone (BGH) polyadenylation sequence ensures high transcription following transduction.
Lot Number	32087
Quantity	0.1 ml (100 μl)
Purity	lodixanol gradient
Titer/Concentration	0.5 x 10 ¹² vg/ml Titered by QPCR by GeneDetect
Product Manufacturer	GeneDetect® www.GeneDetect.com
Presentation	Liquid in phosphate buffered saline (PBS) containing 1mM MgCl2 and Lutrol F68 (0.001%)
Storage & Stability	Upon receipt, briefly spin contents of vial to collect sample, aliquot on ice under sterile conditions and store: 4°C for short term (<1 month), -20°C or -80°C for long term. <u>Avoid repeated</u> <u>freeze-thaw cycles.</u>

Quality Control

$10\mu l$ was analyzed by SDS-PAGE to verify purity.



Handling	Always wear laboratory gloves, protective glasses and a suitable protective laboratory coat when using rAVE [™] reagents. Recent NIH guidelines state that "adeno-associated virus (AAV) types 1 through 4, and recombinant AAV constructs, in which the transgene does not encode either a potentially tumorigenic gene product or a toxin molecule and are produced in the absence of a helper virus" can in most cases be handled at biosafety level 1 (BL1). You should follow the guidelines set by your Institutional biosafety committee for the handling of adeno-associated virus.
Disposal	rAVE™ reagents are susceptible to 5% phenol, 10% bleach, 10% Wescodyne, or Virkon. We recommend using a fresh solution of 10% bleach for 30 minutes for decontamination.
Applications	For <i>in vitro</i> applications, mix 2µl rAVE [™] sample with 200µl pre- warmed culture media and apply per well to cells of 60 – 80% confluency (24well plate). Allow at least three days for viral integration and gene expression before analysis. For <i>in vivo</i> applications, dose should be determined by end user.
References	For a comprehensive list of references refer to www.GeneDetect.com
Initial Characterization Data	Refer to The Michael J. Fox Foundation Research Tools webpage for <i>in vitro</i> and <i>in vivo</i> characterization data.

For research use only, not for clinical or diagnostic use.